Latest & greatest articles for hepatitis

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on hepatitis or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on hepatitis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for hepatitis

181. An updated systematic review and meta-analysis of the prevalence of hepatitis B virus in Ethiopia. (Full text)

An updated systematic review and meta-analysis of the prevalence of hepatitis B virus in Ethiopia. Hepatitis B virus is one of the major public health concerns globally. It is highly infectious and can be transmitted from person to person through vertically or horizontally via contaminated body fluids. Despite the provision of an effective vaccine, it remains a major problem worldwide, particularly among the developing countries.Online electronic databases including PubMed, Google Scholar

2020 BMC infectious diseases PubMed abstract

182. The impact of IFNL3 genotype on interferon treatment outcome in patients chronically infected with hepatitis B virus: A meta-analysis. (Abstract)

The impact of IFNL3 genotype on interferon treatment outcome in patients chronically infected with hepatitis B virus: A meta-analysis. Polymorphisms near the interferon lambda 3 (IFNL3, also known as IL28B) have been proposed to be associated with interferon (IFN)-induced hepatitis C virus (HCV) clearance, but the impact of IFNL3 variations on the result of IFN-based therapy in chronic hepatitis B (CHB) infection is still poor understood.The purpose of this study was to evaluate

2020 Microbial pathogenesis

183. Interventions to Increase Completion of Hepatitis B Vaccination in People who Inject Drugs: A Systematic Review and Meta-analysis. (Full text)

Interventions to Increase Completion of Hepatitis B Vaccination in People who Inject Drugs: A Systematic Review and Meta-analysis. Increases in opioid misuse and injection drug use have resulted in a rise in acute cases of hepatitis B. We conducted a systematic review and meta-analysis of randomized studies to determine the effect (pooled odds ratio) of interventions to increase hepatitis B vaccination completion in people who inject drugs (PWID). Odds ratios from the included studies were (...) combined to create a pooled odds ratio (OR) using the Inverse Heterogeneity Model. Eleven studies met the eligibility criterion of having a randomized intervention to increase hepatitis B virus vaccination completion among PWID. The odds of vaccine completion in the intervention group were greater than in the control/comparison group (pooled OR, 2.53; 95% confidence interval [CI], 1.07-5.99). Subgroup analysis indicated that financial incentives were most effective (OR, 7.01; 95% CI, 2.88-17.06

2020 Open forum infectious diseases PubMed abstract

184. Hepatitis C prevalence among the migrant population in Spain: A systematic review and meta-analysis. (Abstract)

Hepatitis C prevalence among the migrant population in Spain: A systematic review and meta-analysis. Spain, which has one of the largest migrant populations in Europe, has committed to eliminating the hepatitis C virus (HCV). The aim of this study was to estimate the prevalence of HCV among migrant groups in Spain, a country of 46 million people, with an estimated HCV-antibody prevalence of 1.7%.Studies on HCV and migration in Spain were identified by systematically searching three databases

2020 Enfermedades infecciosas y microbiologia clinica

185. Liver Resection for Colorectal Hepatic Metastases after Systemic Chemotherapy and Selective Internal Radiation Therapy with Yttrium-90 Microspheres: A Systematic Review. (Abstract)

Liver Resection for Colorectal Hepatic Metastases after Systemic Chemotherapy and Selective Internal Radiation Therapy with Yttrium-90 Microspheres: A Systematic Review. Selective internal radiation therapy (SIRT) using yttrium-90 resin microspheres has been used together with systemic chemotherapy to treat patients with unresectable liver metastases. This study undertook the first systematic pooled assessment of the case profile, treatment and outcome in patients with initially inoperable (...) colorectal hepatic metastases undergoing resection after systemic chemotherapy and SIRT.A systematic review of the literature was performed using Medline and Embase for publications between January 1998 and August 2017. Keywords and MESH headings "SIRT", "Yttrium-99 radio embolization" and "liver metastases" were used. Reports on patients undergoing liver resection after SIRT for colorectal liver metastases were included. Case reports, reviews and papers without original data were excluded. The study

2020 Digestive surgery

186. Infants born to hepatitis B-infected mothers: immunoglobulin policy

Infants born to hepatitis B-infected mothers: immunoglobulin policy Infants born to hepatitis B-infected mothers: immunoglobulin policy - GOV.UK Tell us whether you accept cookies We use about how you use GOV.UK. We use this information to make the website work as well as possible and improve government services. Accept all cookies You’ve accepted all cookies. You can at any time. Hide Search Guidance Infants born to hepatitis B-infected mothers: immunoglobulin policy Policy on the use (...) of passive immunisation with hepatitis B immunoglobulin (HBIG) for infants born to hepatitis B infected mothers. Published 12 August 2008 Last updated 17 January 2020 — From: Documents If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email . Please tell us what format you need. It will help us if you say what assistive technology you use. Details This document summarises the policy and evidence for passive immunisation

2020 Public Health England

187. Givosiran (Givlaari) - acute hepatic porphyria

Givosiran (Givlaari) - acute hepatic porphyria Drug Approval Package: GIVLAARI (givosiran)Injection U.S. Department of Health and Human Services Search FDA Submit search Drug Approval Package: GIVLAARI (givosiran)Injection Company: Alnylam Pharmaceuticals Inc. Application Number: 212194 Approval Date: 11/20/2019 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. FDA Approval Letter and Labeling (PDF) (PDF) FDA Application Review Files

2020 FDA - Drug Approval Package

188. The absence of the common hepatic artery and its implications for surgical practice: Results of a systematic review and meta-analysis. (Abstract)

The absence of the common hepatic artery and its implications for surgical practice: Results of a systematic review and meta-analysis. The common hepatic artery (CHA) is the main arterial supply to the liver. Common classifications of the anatomical variations of the celiac trunk have only marginally described the CHA. Currently, the only classification addressing anatomical variants in cases of CHA absence from the celiac trunk is that reported by Huang et al. In this systematic review

2019 The surgeon : journal of the Royal Colleges of Surgeons of Edinburgh and Ireland

189. Role of tenofovir disoproxil fumarate in prevention of perinatal transmission of hepatitis B virus from mother to child: a systematic review and meta-analysis. (Full text)

Role of tenofovir disoproxil fumarate in prevention of perinatal transmission of hepatitis B virus from mother to child: a systematic review and meta-analysis. To prevent the perinatal transmission of hepatitis B virus (HBV) from mother to child, administration of an antiviral agent during pregnancy has been attempted in women who are either hepatitis B e antigen positive or have a high viral load. In this systematic review and meta-analysis with randomized controlled trials, we analyzed

2019 The Korean journal of internal medicine PubMed abstract

190. Hepatitis C Virus Screening and Care: Complexity of Implementation in Primary Care Practices Serving Disadvantaged Populations. (Abstract)

Hepatitis C Virus Screening and Care: Complexity of Implementation in Primary Care Practices Serving Disadvantaged Populations. Hepatitis C virus (HCV) disproportionately affects disadvantaged communities.To examine processes and outcomes of Screen, Treat, Or Prevent Hepatocellular Carcinoma (STOP HCC), a multicomponent intervention for HCV screening and care in safety-net primary care practices.Mixed-methods retrospective analysis.5 federally qualified health centers (FQHCs) and 1 family

2019 Annals of Internal Medicine

191. Use of hepatitis A vaccine for post-exposure prophylaxis in individuals over 40 years of age: A systematic review of published studies and recommendations for vaccine use. (Abstract)

Use of hepatitis A vaccine for post-exposure prophylaxis in individuals over 40 years of age: A systematic review of published studies and recommendations for vaccine use. Hepatitis A can cause widespread outbreaks. Until 2018, postexposure prophylaxis (PEP) in the United States for individuals >40 years consisted of immune globulin (IG) administered as soon as possible after exposure, ideally within 14 days whereas those aged ≤40 should receive hepatitis A (HepA) vaccine. However, state (...) health departments reporting difficulty quickly accessing and administering IG, costs of higher IG doses and importance of long-term HAV protection prompted CDC to review immunogenicity data for use of HepA vaccine for PEP in older adults. We reviewed literature on use of HepA vaccine in adults >40 years and existing recommendations for HepA vaccine for use as PEP in other countries.We searched PubMed and EMBASE from January 1, 1992-January 7, 2017 using the terms "hepatitis A vaccine∗" and "HAV

2019 Vaccine

192. Response to hepatitis B vaccination in patients with liver cirrhosis. (Abstract)

Response to hepatitis B vaccination in patients with liver cirrhosis. Hepatitis B vaccination is strongly recommended for all infants and children but also for adults who are at risk of HBV infection. Attempts to immunize patients with liver cirrhosis have been proven relatively ineffective, and several strategies have already been used to improve the immune response in this group. The primary aim of this review is to examine, discuss, and summarize the immunogenicity of hepatitis B vaccination

2019 Reviews in medical virology

193. Global burden of hepatitis B infection in people living with HIV: a systematic review and meta-analysis. (Abstract)

Global burden of hepatitis B infection in people living with HIV: a systematic review and meta-analysis. This systematic review and meta-analysis was conducted to estimate the prevalence and burden of HBV infection in PLWH at global, regional, and national levels.We searched of PubMed, Excerpta Medica Database, Web of Science, and Global Index Medicus to identify studies published between January 01, 1990 and December 31st, 2017. HBV infection (HBs antigen) had to be diagnosed with serological

2019 Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

194. Carfilzomib (Kyprolis): risk of reactivation of hepatitis B virus

Carfilzomib (Kyprolis): risk of reactivation of hepatitis B virus Carfilzomib (Kyprolis▼): risk of reactivation of hepatitis B virus - GOV.UK GOV.UK uses cookies which are essential for the site to work. We also use non-essential cookies to help us improve government digital services. Any data collected is anonymised. By continuing to use this site, you agree to our use of cookies. Accept cookies You’ve accepted all cookies. You can at any time. Hide Search Carfilzomib (Kyprolis▼): risk (...) of reactivation of hepatitis B virus Establish hepatitis B status before initiating carfilzomib and in patients with unknown hepatitis B virus serology who are already being treated with carfilzomib. Published 21 November 2019 From: Therapeutic area: , , , Contents Advice for healthcare professionals: hepatitis B virus reactivation has been reported in patients treated with carfilzomib screen all patients for hepatitis B virus before initiation of carfilzomib; patients with unknown serology who are already

2019 MHRA Drug Safety Update

195. Glecaprevir/pibrentasvir (chronic hepatitis C in adolescents) - Benefit assessment according to §35a Social Code Book V

Glecaprevir/pibrentasvir (chronic hepatitis C in adolescents) - Benefit assessment according to §35a Social Code Book V Extract 1 Translation of Sections 2.1 to 2.6 of the dossier assessment Glecaprevir/Pibrentasvir (chronische Hepatitis C bei Jugendlichen) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 11 July 2019). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative (...) and legally binding. IQWiG Reports – Commission No. A19-33 Glecaprevir/pibrentasvir (chronic hepatitis C in adolescents) – Benefit assessment according to §35a Social Code Book V 1 Extract of dossier assessment A19-33 Version 1.0 Glecaprevir/pibrentasvir (chronic hepatitis C in adolescents) 11 July 2019 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Glecaprevir/pibrentasvir (chronic hepatitis C

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

196. Hepatitis B: the green book, chapter 18

Hepatitis B: the green book, chapter 18 Hepatitis B: the green book, chapter 18 - GOV.UK GOV.UK uses cookies which are essential for the site to work. We also use non-essential cookies to help us improve government digital services. Any data collected is anonymised. By continuing to use this site, you agree to our use of cookies. Accept cookies You’ve accepted all cookies. You can at any time. Hide Search Guidance Hepatitis B: the green book, chapter 18 Hepatitis B immunisation information (...) for public health professionals. Published 20 March 2013 Last updated 18 November 2019 — From: Documents If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email . Please tell us what format you need. It will help us if you say what assistive technology you use. Details is an infection of the liver caused by the hepatitis B virus (HBV). Published 20 March 2013 Last updated 18 November 2019 18 November 2019 Removed previous

2019 Public Health England

197. Practice Advisory: Hepatitis B Prevention

Practice Advisory: Hepatitis B Prevention Practice Advisory: Hepatitis B Prevention - ACOG Menu ▼ Practice Advisory: Hepatitis B Prevention Page Navigation ▼ Share: Practice Advisory: Hepatitis B Prevention The Centers for Disease Control and Prevention (CDC) and the Advisory Committee on Immunization Practices (ACIP) have released updated guidance on preventing the transmission of hepatitis B virus (HBV) infection (1). A critical element of the strategy to eliminate HBV in the United States (...) is the prevention of perinatal transmission. The CDC and ACIP’s updated guidance reflects the best currently available evidence and select new or updated recommendations include the following: Pregnant women positive for hepatitis B surface antigen (HBsAg) should be tested for hepatitis B virus deoxyribonucleic acid (HBV DNA) to guide the use of antiviral medication to prevent perinatal transmission Persons with chronic liver disease* should be vaccinated against HBV The American Association for the Study

2019 American College of Obstetricians and Gynecologists

198. Lactulose Management of Minimal Hepatic Encephalopathy: A Systematic Review. (Abstract)

Lactulose Management of Minimal Hepatic Encephalopathy: A Systematic Review. Minimal hepatic encephalopathy has been shown to increase risk of involvement in road traffic accidents and alter quality of life. This systematic review focused on the role of nonabsorbable disaccharides for the management of minimal hepatic encephalopathy. Randomized clinical trials that evaluated medical management of minimal hepatic encephalopathy were considered for inclusion. Individual studies compared lactulose (...) with usual care and lactulose with probiotics and L-ornithine-L-aspartate. The outcome for examination was the neuropsychiatric test for cognitive function. Search strategies outlined by the Johanna Briggs Institute were used, and articles and references of selected articles were reviewed according to that methodology. Meta-analyses and narrative synthesis of the included studies were undertaken. Treatment of minimal hepatic encephalopathy with lactulose, probiotics, or L-ornithine-L-aspartate was seen

2019 Gastroenterology nursing : the official journal of the Society of Gastroenterology Nurses and Associates

199. A meta-analysis of laparoscopic versus open left lateral hepatic sectionectomy. (Full text)

A meta-analysis of laparoscopic versus open left lateral hepatic sectionectomy. This study aimed to assess the perioperative outcomes of laparoscopic left lateral sectionectomy (LLLS) compared with an open (OLLS) approach.A systematic literature search was performed in PubMed, Scopus and Cochrane library, in accordance with the PRISMA guidelines. The Odds Ratio (ORs), the weighted mean difference (WMD) and 95% confidence interval (95% CI) were evaluated, by means of Random-Effects model.Ten

2019 HPB : the official journal of the International Hepato Pancreato Biliary Association PubMed abstract

200. Different Hepatitis C Virus Infection Statuses Show a Significant Risk of Developing Type 2 Diabetes Mellitus: A Network Meta-Analysis. (Abstract)

Different Hepatitis C Virus Infection Statuses Show a Significant Risk of Developing Type 2 Diabetes Mellitus: A Network Meta-Analysis. The role of hepatitis C virus (HCV) infection statuses in the development of type 2 diabetes mellitus (T2DM) has not been completely understood.To evaluate the prevalence of T2DM in patients with different HCV infection statuses.We conducted a systematic study on T2DM risk in five types of individuals with different HCV infection statuses: non-HCV controls, HCV

2019 Digestive diseases and sciences